ORIGINAL ARTICLE

Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes

Bingtao Zhai1,2,3,4*, Qibiao Wu3*, Wengang Wang1,2,4, Mingming Zhang2,4, Xuemeng Han2,4, Qiujie Li2,4, Peng Chen2,4, Xiaying Chen2,4, Xingxing Huang2, Guohua Li2,4, Qin Zhang2,4, Ruonan Zhang2,4, Yu Xiang2,4, Shuiping Liu2,4, Ting Duan2,4, Jianshu Lou2,4, Tian Xie1,2,4, Xinbing Sui2,4

1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; 2Department of Holistic Integrative Pharmacy Institutes and Comprehensive Cancer Diagnosis and Treatment Center, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou 310018, China; 3State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 519020, China; 4Key Laboratory of Elemene Class Anticancer Chinese Medicine of Zhejiang Province and Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou 310018, China

ABSTRACT

Objective: This study aimed to develop a new polyethylene glycol (PEG)ylated β-elemene liposome (PEG-Lipo-β-E) and evaluate its characterization, pharmacokinetics, antitumor effects and safety in vitro and in vivo.

Methods: The liposomes were prepared by ethanol injection and high-pressure micro-jet homogenization. Characterization of the liposomes was conducted, and drug content, entrapment efficiency (EE), in vitro release and stability were studied by ultra-fast liquid chromatography (UFLC) and a liquid surface method. Blood was drawn from rats to establish the pharmacokinetic parameters. The anticancer effect was evaluated in a KU-19-19 bladder cancer xenograft model. Histological analyses were performed to evaluate safety.

Results: The PEG-Lipo-β-E showed good stability and was characterized as 83.31 ± 0.181 nm in size, 0.279 ± 0.004 in polydispersity index (PDI), −21.4 ± 1.06 mV in zeta potential, 5.024 ± 0.107 mg/mL in β-elemene (β-E) content, and 95.53 ± 1.712% in average EE. The Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) indicated the formation of PEG-Lipo-β-E. Compared to elemene injection, PEG-Lipo-β-E demonstrated a 1.75-fold decrease in clearance, a 1.62-fold increase in half-life, and a 1.76-fold increase in area under the concentration-time curves (AUCs) from 0 hour to 1.5 hours (P < 0.05). PEG-Lipo-β-E also showed an enhanced anticancer effect in vivo. Histological analyses showed that there was no evidence of toxicity to the heart, kidney, liver, lung or spleen.

Conclusions: The present study demonstrates PEG-Lipo-β-E as a new formulation with ease of preparation, high EE, good stability, improved bioavailability and antitumor effects.

KEYWORDS

β-elemene; PEGylated liposome; pharmacokinetics; antitumor effect; bladder cancer

Introduction

Elemenes are a group of natural compounds extracted from the herb Curcumae Rhizoma. Elemene contains 3 major components: α-, β-, and δ-elemene. Among them, β-elemene (β-E) has the highest antitumor activity1. The chemical name of β-E is 1-methyl-1-vinyl-2,4-diisopropenyl-cyclohexane, the molecular formula is C15H24, and the molecular weight (MW) is 204.35 g/mol2. β-E has been shown to inhibit tumor cell growth by targeting the Wnt/β-catenin3-6, Notch7-9, PI3K/AKT/mTOR10-12, MAPK/ERK13-15, NF-κB16 and STAT3 pathways17-19. β-E also increases the sensitivity of tumor cells to chemoradiotherapy, reverses chemotherapeutic multiple-drug resistance and regulates tumor-associated immune responses20-23.

However, the clinical application of elemene has been limited by its poor solubility in water, poor stability, and low bioavailability24. Currently, an elemene emulsion injection and
an oral emulsion have been developed to treat various cancers
in the clinic for > 20 years. Although the emulsion increases
the bioavailability of β-E, it is easily cleared by the kidneys
and taken up by the reticuloendothelial system (RES) residing
in the liver and the spleen because of the small particle size.
Some symptoms may also occur upon oral or intravenous
(iv) administration, including phlebitis, fever, pain, allergy,
bleeding, nausea, vomiting, leukocytopenia, baldness, and
liver dysfunction25. Therefore, it is necessary to study novel
formulations for β-E to extend its plasma circulation lifetime
and to enhance its therapeutic activity at doses exhibiting
acceptable toxicities.

In the area of cancer therapy, several polymers have
successfully been used as carriers for sustained drug delivery.
For example, polyethylene glycol (PEG) and its derivatives such
as monoo methoxy poly (ethylene glycol)-poly (e-caprolactone)
(mPEG-PCL), and poly lactic-co-glycolic acid (PLGA). These
copolymers are not accumulative in vivo because they can be
eliminated by the kidneys or their degradation products can
enter the tricarboxylic acid cycle26-29. Among the different ways
investigated in the attempt to improve the blood circulation
time of anticancer drugs, anchoring the PEG on the surface
of drug delivery systems is the most widely used method,
especially on the surface of liposomes.

Liposomes are spherical vesicles created by a lipid bilayer
of phospholipids. Due to their good biocompatibility, weak
immunogenic response, and low intrinsic toxicity, liposomes
have become one of the best choices for pharmaceutical
 carriers30. Recently, to improve the antitumor effects and to
overcome the shortcomings of conventional vesicles being
easily adsorbed by plasma proteins and rapidly cleared by
organs such as the liver and spleen, researchers have obtained
long-circulating liposomes by grafting the surface with PEG, which shields the vesicles from interaction with
macrophages and creates a long circulating “stealth” effect. For
instance, DOXIL/Caelyx is a PEGylated liposomal doxorubicin,
which is composed of hydrogenated soybean phospholipids,
cholesterol, mPEG2000-DSPE and has been approved in both
the USA and Europe for the treatment of Kaposi’s sarcoma
and recurrent ovarian cancer31. The long circulation time and
improved stability allow the vesicles to extravasate to the tumor
site and be retained for days32-34. In this study, we aimed to
develop a PEGylated β-E liposome to prolong the half-life of
the liposomes in plasma and enhance their anticancer effects.
P EG-Lipo-β-E was prepared, and the physical properties such
as particle size, zeta potential, polydispersity index (PDI) and
others were evaluated. In addition, its pharmacokinetics,
anticancer effects and safety were investigated to estimate the
potential efficacy for clinical use.

**Materials and methods**

**Materials**

β-E standard (99.4% pure; National Institute for the
Control of Pharmaceutical and Biological Products, Beijing,
China), β-E crude drug (99.1% pure; Jusheng Technology
Co., Hubei, China), elemene injection (0.1 g/20 mL, Dalian
Holley King Kong Pharmaceutical Co., Dalian, China),
acetonitrile (Merck Co., Ltd, Darmstadt, Germany), soybean
lecithin (Tywei, Shanghai, China), cholesterol (99.5% pure,
Dingguo Changsheng Biotechnology Co., Beijing, China),
Lipoid DSPE-PEG 2000 (Lipoid GmbH, Ludwigshafen,
Germany), L-histidine (Sinopharm Chemical Reagent Co.,
Shanghai, China), Kolliphor® hydroxystearate (HS) 15 (BASF,
Ludwigshafen, Germany), 95% ethanol (Sinopharm Chemical
Reagent Co., Shanghai, China), RPMI 1640 (Gibco, Waltham,
MA, USA), and fetal bovine serum (FBS) (Gibco, Waltham,
MA, USA) were obtained. All other reagents
used in this study were of analytical grade and were used
without further purification. The water used in this study was
filtered using a Millipore Milli-Q™ water purification system
(Millipore Corp., Milford, MA, USA).

**Rats and mice**

Male Sprague Dawley rats and female BALB/c mice (6 to 8
weeks old) were purchased from the Institute of Experimental
Animals of the Zhejiang Academy of Medical Sciences and
housed in a standard polypropylene cage containing sterile
bedding under controlled temperature (23 ± 2) °C and
humidity (50% ± 5)%. All experimental procedures were
approved by the Medical Ethics Committee of the Hangzhou
Normal University (Approval No. 2017052).

**Preparation of PEG-Lipo-β-E**

The oil phase containing 0.5 g of β-E, 2.5 g of soybean
lecithin, 0.1 g of cholesterol, and 0.2 g of DSPE-PEG 2000 was
dissolved in 2 mL of 95% ethanol in an 80 °C water bath. The
aqueous phase was prepared by adding 10 mM L-histidine to
100 mL of water, followed by adjusting the pH to 6.5. The oil
phase and aqueous phase were mixed slowly at 60 °C, and the liposomes were formed using an Ultra-Turrax T18 high-speed blender (IKA, Staufen, Germany) at 13,700 g for 60 minutes. The liposomes were passed through an LM20 microfluidizer (Microfluidics Co., Westwood, MA, USA) at a pressure of 15,000 psi for 3 cycles, and then the solution was filtered through a 0.22 µm filter.

**Characterization of PEG-Lipo-β-E**

The morphology of PEG-Lipo-β-E was determined using a transmission electron microscope (TEM) (HT-7700, Hitachi, Japan). The mean particle size, zeta potential and PDI of lipidosome droplets were determined by a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). The pH values of the samples were measured using a pH meter at (20 ± 1) °C (PB-10, Sartorius, Goettingen, Germany).

**Fourier transform infrared spectroscopy (FTIR)**

The FTIR spectrum of the pure drug, physical mixture (β-E/soybean lecithin/cholesterol/DSPE-PEG 2000) and the PEG-Lipo-β-E was obtained using an FTIR spectrophotometer (Alpha, Bruker, Germany)35. The PEG-Lipo-β-E was freeze-dried before measurement (Alpha 1-2 LD plus, Martin Christ, Germany). The samples were crushed to a fine powder, mullied with anhydrous potassium bromide, pressed to form a thin pellet, and the spectra were obtained in the wavenumber region between 4,000 and 400 cm\(^{-1}\).

**Differential scanning calorimetry (DSC)**

Thermal analysis of PEG-Lipo-β-E was performed using a differential scanning calorimeter (TA Q200, USA). The samples were weighed, filled in aluminum pans, sealed, and analyzed at a heating rate of 5 °C/minute from 0 to 80 °C. To evaluate any changes during formulation, DSC measurement was also performed for soybean lecithin, cholesterol, PEG-Lipo (blank liposomes) and physical mixture of the formulation components36.

**Ultra-fast liquid chromatography (UFLC) analysis of β-E in PEGylated liposomes and rat plasma**

According to the literature37, the drug content was detected by UFLC (Shimadzu Co., Ltd., Kyoto, Japan). The chromatographic conditions were set as follows: C18 column (2.2 µm, 75 mm × 3.0 mm), acetonitrile/water (80:20) as the mobile phase, 40 °C as the column temperature, 210 nm as the detection wavelength, 1.0 mL/minute as the flow rate, and 3 µL as the injection volume.

**Content and entrapment efficiency of PEG-Lipo-β-E**

To determine the drug content of PEG-Lipo-β-E, 0.2 mL of the PEGylated liposomes was taken and diluted to 100 mL with an 80% acetonitrile aqueous solution. One milliliter of this sample was determined by UFLC, and this procedure was repeated 3 times.

The EE of β-E in the PEGylated liposomes was determined as previously reported by the liquid surface method37. Free β-E was insoluble in water and floated on the surface of the aqueous phase; thus, the internal solution of the liposomes was taken to determine the EE. The sample (2 mL) was moved into a tube and allowed to stand for 2 hours at room temperature. Then, 0.1 mL of the internal solution was removed and diluted to 50 mL with an 80% acetonitrile aqueous solution to be measured for β-E content as “a”. The remaining solution (1.9 mL) was also diluted to 50 mL with the 80% acetonitrile aqueous solution. Then, 1 mL of the second diluted sample was removed and diluted again to 25 mL to measure the β-E content as “b”. After repeating once as above, the average EE was calculated using the following equations:

\[
C_{internal} = \frac{a \times 50}{0.1}
\]

\[
W_{entrapment} = C_{internal} \times (2 \text{ mL} - V_{free}) = 500 \times a \times (2 \text{ mL} - V_{free})
\]

\[
W_{total} = a \times 50 + b \times 25 \times 50
\]

\[
EE = \frac{W_{entrapment}}{W_{total}} \times 100% = \frac{10 \times a \times (2 - V_{free})}{(a + 25b)} \times 100%
\]

Here, \(V_{free}\) is the volume of β-E at the liquid surface. Because the volume of β-E was found to be insignificant on the surface of PEG-Lipo-β-E (at least 0.05 mL), the EE should be more than \(19.5 \times a/(a + 25b) \times 100\%\).

**In vitro release of β-E from the PEGylated liposomes**

The in vitro release profile of β-E from the liposomes was assessed by determining the residual amount of β-E in the liposomes38. Briefly, 200 µL of PEG-Lipo-β-E or elemene injection (5 mg/mL)
was placed in 5 dialysis bags (MW cutoff 12,000–14,000 Da), ligated, immersed in the 0.5% HS 15 release media (2,500 mL) and stirred by magnetic force at 25 °C. Samples were taken out at predetermined time intervals of 0, 4, 8, 12, 24, and 36 hours. The aqueous dispersion in the dialysis bag was transferred to a 10 mL volumetric flask, and the remains in the bag were washed into the same volumetric flask with a small amount of release media. Then, 5 mL of ethanol was added to the flask to extract the drug dissolved in the release media. The supernatants were filtered through 0.22 µm microporous membranes and subjected to UFLC analysis for the determination of \( \beta \)-E. The in vitro release of \( \beta \)-E from the PEGylated liposomes and elemene injection was repeated 3 times.

Stability studies

Three batches of PEG-Lipo-\( \beta \)-E suspension were prepared according to the mentioned procedure, stored in a 4 °C refrigerator, and removed after 7 days, 15 days, and 30 days. The appearance of the liposomes was observed, and the EE, particle size, and content of \( \beta \)-E were determined.

Pharmacokinetics of PEG-Lipo-\( \beta \)-E

For the pharmacokinetics study, 10 male Sprague Dawley rats weighing 180–200 g were divided randomly into an elemene injection group (5 rats) and a PEG-Lipo-\( \beta \)-E group (5 rats) for iv injection of \( \beta \)-E (40 mg/kg). Blood (0.5 mL) was obtained from the ocular vein of the rats at 5, 10, 20, 30, 40, 60, and 90 minutes after iv administration. Then, plasma was obtained after centrifugation at 4,000 × g for 10 minutes at 4 °C. A mixture of 0.2 mL of plasma and 0.8 mL of acetonitrile was oscillated for 2 minutes and then centrifuged at 12,000 × g for 10 minutes at 4 °C. The supernatant was taken and filtered through a 0.22 µm filter. The filtrate was used for the determination of \( \beta \)-E in plasma.

In vitro cell migration assay

The inhibitory effect of PEG-Lipo-\( \beta \)-E on the migration of bladder cancer cells was measured by wound healing and Transwell migration assays. Bladder cancer KU-19-19 cells were used in this test. For the wound healing assay, cells were seeded at a density of \( 1.5 \times 10^6 \) cells per well on 6-well plates and were cultured until they reached 80%–90% confluency. Then, the media was removed, and a sterile 200 µL pipette tip was applied to scratch a vertical wound. The cells were washed with phosphate-buffered saline (PBS) 3 times and incubated with blank PEGylated liposomes, free \( \beta \)-E or PEG-Lipo-\( \beta \)-E (at an equivalent \( \beta \)-E dose of 30 µg/mL for KU-19-19 cells). In contrast, cells that did not receive any treatment after the scratches were used as negative controls. Images were captured at 0 hour and 36 hours after the treatment with an inverted microscope (Carl Zeiss, Jena, Germany).

For the Transwell migration assay, \( 2 \times 10^5 \) cells were seeded in the upper chamber of Transwell plates (24-well insert, pore size, 8 µm, Corning, USA). A total of 100 µL of serum-free media with PEG-Lipo, free \( \beta \)-E or PEG-Lipo-\( \beta \)-E (at an equivalent \( \beta \)-E dose of 30 µg/mL) was added into the upper chamber, while 600 µL of complete medium containing 10% FBS was loaded into the lower chamber as a chemoattractant. The cells without any treatment were used as controls. After 36 hours, the upper medium was removed, and a cotton swab was applied to remove the remaining cells. Then, the Transwell chambers were slightly washed in PBS, fixed using 4% paraformaldehyde for 20 minutes and stained with crystal violet for 20 minutes. Finally, the upper chambers were washed with PBS twice, and the stained Transwell chambers were visualized under a microscope (Nikon Eclipse Ci-S, Tokyo, Japan).

In vivo antitumor efficacy

Evaluation of the in vivo antitumor efficacy was based on the determination of the tumor volume (TV), calculated as
previously described\textsuperscript{41}, where \( TV = 0.5 \times (d_1 \times d_2^2) \), with \( d_1 \) and \( d_2 \) being the largest and the smallest perpendicular diameters, respectively. Briefly, KU-19-19 cells [obtained from the American Type Culture Collection (ATCC)] were injected into the abdominal cavity of mice for 6–8 days before they were collected and resuspended in PBS. BALB/c nude female mice were divided into 3 groups (5 mice/group), followed by subcutaneous inoculation with KU-19-19 tumor cells into the right axilla at a volume of 0.2 mL (2.5 \( \times \) \( 10^6 \) cells/mL). After inoculation, groups 1 and 2 were continuously injected with either elemene injection (\( \beta \)-E equivalent dose of 50 mg/kg), PEG-Lipo-\( \beta \)-E (\( \beta \)-E equivalent dose of 50 mg/kg) or PEG-Lipo (blank liposomes) via intraperitoneal injection. Tumor growth was monitored every 4 days. Sixteen days later, all of the animals were sacrificed by cervical dislocation, and the tumors were isolated and weighed. Alterations in the TV were determined by considering the initial volume as 100% and calculating the percent increase or decrease according to this initial volume. The relative tumor volume (RTV) and the percent of tumor growth inhibition (TGI) for each experimental group were calculated using the following equations:

\[
RTV = \frac{TV \text{ on day 16}}{TV \text{ on day 0}}
\]

\[
TGI = 1 - \frac{RTV \text{ from each treatment}}{RTV \text{ of negative control group}} \times 100\%\]

Histological analysis

After the end of the treatment (day 16), the animals were anesthetized and euthanized. Heart, kidney, liver, lung, and spleen tissues were collected and fixed in paraformaldehyde (4% w/v in PBS) to investigate the toxicity. Then, these tissues were embedded in paraffin blocks, sectioned into 5-µm thick slices, placed onto glass slides, and stained with hematoxylin-eosin. The body weight was measured every 4 days.

Statistical analysis

The data were statistically analyzed by SPSS Version 17.0 SPSS (SPSS Inc. Chicago, IL, USA). All analyses were carried out in triplicate, and the results are reported as the mean ± standard deviation (SD). Statistical analysis of the pharmacokinetic study was carried out using DAS 2.0 software (Drug and Statistics software, Shaanxi University of Traditional Chinese Medicine, Shaanxi, China). A value of \( P < 0.05 \) was regarded as a significant difference.

Results

Preparation and characterization of PEG-Lipo-\( \beta \)-E

In the present study, PEGylated liposomes were prepared by ethanol injection and high-pressure micro-jet homogenization. The schematic diagram of PEG-Lipo-\( \beta \)-E is presented in Figure 1A. The ration of soybean lecithin, cholesterol, DSPE-PEG 2000 and \( \beta \)-E was 25:1:2:5. DSPE-PEG 2000 (2%) was added to the liposomes to exert a long-circulating effect. As shown in Figure 1B, PEG-Lipo-\( \beta \)-E is a milky white liquid. The TEM imaging shows that the liposomes are round in shape with a uniform size (Figure 1C). The mean diameter of the freshly prepared liposomes was 83.31 ± 0.181 nm with a particle diameter size that ranged from 10 to 400 nm (Figure 1D), and the PDI value was 0.279 ± 0.004, indicating that its particle size distribution is acceptable and indicating a homogenous population of phospholipid vesicles\textsuperscript{42}. The zeta potential of the liposomes was −21.4 ± 1.060 mV, indicating a negatively charged surface on the liposomes (Figure 1E). The pH was 6.65 ± 0.020. FTIR

The FTIR technique can be used to explain the mechanism of encapsulating by exploring the interactions among the liposome components. The FTIR spectra obtained for the pure drug, physical mixture and liposomes are shown in Figure 2. It can be observed from the spectra that many peaks related to the \( \beta \)-E (from 3080 to 889 cm\(^{-1}\)) did not appear in the spectra of PEG-Lipo-\( \beta \)-E, probably due to the drug being encapsulated in the formulations or covered by other ingredients in the liposomes. In the spectra obtained for \( \beta \)-E, the physical mixture and PEG-Lipo-\( \beta \)-E, the bands at 1737 and 1641/1639 cm\(^{-1}\) indicated the presence of the C=O, C=O and NH\(_2\) in the \( \beta \)-E, DSPE and soybean lecithin, but the peak at 1639 cm\(^{-1}\) in liposomes was significantly reduced, indicating interaction between liposome components. The asymmetric stretching vibration of the P=O group could be identified by a peak near 1200 cm\(^{-1}\). In the spectra obtained for physical mixture and PEG-Lipo-\( \beta \)-E, this peak was at 1240 cm\(^{-1}\) and 1230 cm\(^{-1}\), respectively. In addition, the peaks at 2858/2854 and 2932/2927/2926 cm\(^{-1}\) were present in the spectra of the pure drug, physical mixture and the PEG-Lipo-\( \beta \)-E. These peaks were related to the symmetric and asymmetric CH\(_2\) stretching vibrations in the aliphatic structure of the PEG,
Figure 1 The characterization of PEG-Lipo-β-E. (A) The schematic diagram of PEG-Lipo-β-E. (B) The appearance of PEG-Lipo-β-E. (C) TEM analysis of PEG-Lipo-β-E (5,000 ×). (D) Particle size of PEG-Lipo-β-E. (E) Zeta potential of PEG-Lipo-β-E. PEG, polyethylene glycol; β-E, β-elemene.

DSPE and β-E. These results preliminarily indicate that β-E is encapsulated in PEGylated liposomes.

DSC

DSC is a very useful tool to investigate the interaction between liposomes and drug molecules and provides information about the physicochemical state of nanoparticles. A thermogram of soybean lecithin, cholesterol, a physical mixture of β-E/soybean lecithin/cholesterol/DSPE-PEG 2000, PEG-Lipo and PEG-Lipo-β-E are presented in Figure 3. As shown in Figure 3A and 3B, soybean lecithin and cholesterol exhibit a single endothermic peak at temperature of 36.83 °C and 42.34 °C, respectively.

Figure 2 FTIR spectrum of (A) β-E, (B) physical mixture (β-E/soybean lecithin/cholesterol/DSPE-PEG 2000) and (C) PEG-Lipo-β-E.

Figure 3 DSC chromatogram of (A) soybean lecithin, (B) cholesterol, (C) physical mixture (β-E/soybean lecithin/cholesterol/DSPE-PEG 2000), (D) PEG-Lipo and (E) PEG-Lipo-β-E.
The DSC curve of PEG-Lipo-β-E exhibits a high-intensity sharp endothermic peak at a temperature of 46.14 °C, which is significantly different from the peak of the soybean lecithin, cholesterol and the physical mixture. This peak is also detected in the thermogram of the PEG-Lipo, although the peak becomes less intensive. These changes can be attributed to the possible interaction between the liposomal components such as soybean lecithin, cholesterol, DSPE-PEG 2000 and the drug.

Content and entrapment efficiency of PEG-Lipo-β-E

In this study, UFLC was used to determine the drug content in the PEGylated liposomes and rat plasma (Figure 4). Methodological verification showed that the specificity, linearity, limit of quantitation, precision and accuracy, recovery and matrix effects, stability and durability were all in compliance with the requirements (Tables 1–4 and Supplementary Tables S1–S5). The content of β-E in the PEGylated liposomes was 5.024 ± 0.107 mg/mL, which is equal to the commercial elemene injection. The EE of PEG-Lipo-β-E was obtained by determining the drug concentration of the internal and total solutions using the liquid surface method. The average EE of β-E was (95.53 ± 1.712)%.

In vitro release of β-E from PEGylated liposomes

A PBS pH 7.4 solution containing 0.5% HS 15 was chosen as the dialysis medium for the in vitro release of β-E from PEGylated liposomes. The solubility of β-E in the release media could fulfill sink conditions without obviously changing the physical state of the liposomes. The percent of release was calculated by determining the remaining drug in the dialysis bag because of the instability of the drug in the release medium. The in vitro release behavior of the

### Table 1

| Nominal concentration (μg/mL) | Precision (%) | Accuracy (%) |
|------------------------------|---------------|--------------|
| LQC (0.6)                    | 2.0           | 103.8        | 105.0        |
| MQC (2)                      | 1.2           | 97.3         | 100.4        |
| HQC (10)                     | 2.3           | 99.5         | 99.5         |

LQC, low quality control; MQC, middle quality control; HQC, high quality control.

### Table 2

| Nominal concentration (μg/mL) | Calculated concentration (μg/mL) | Recovery (%) | Matrix effect (%) |
|------------------------------|----------------------------------|--------------|-------------------|
| LQC (0.6)                    | 0.6 ± 0.1                        | 97.0 ± 2.1   | 96.3 ± 6.0        |
| MQC (2)                      | 1.9 ± 0.1                        | 96.6 ± 1.2   | 99.33 ± 1.1       |
| HQC (10)                     | 10.4 ± 0.2                       | 101.6 ± 2.3  | 101.6 ± 1.3       |

LQC, low quality control; MQC, middle quality control; HQC, high quality control.
conventional injection and PEGylated liposomes was studied, and the results are depicted in Figure 5A. The elemene injection showed 90% drug release after 36 hours. The PEGylated liposome showed a drug release of only 66% after 36 hours, and this can be attributed to the slower diffusion of the drug from the liposomes with the addition of DSPE-PEG 2000. There was a sharp increase in the drug release after 24 hours for the conventional injection. The more rapid drug release might be due to leakage of the drug from the lipid bilayer, which acts as a rate-limiting membrane for the release of the encapsulated drug. The drug release profile can reflect the distribution of the drug in the vehicle. Drugs that are not completely encapsulated in the lipid matrix have a burst release. The release profile of β-E from the liposomes was steady during the test time, which suggests that β-E might be homogeneously dispersed in the lipid matrix. The obtained release data were fitted to zero-order, first-order, Higuchi, and Weibull equations45, and the results showed that β-E release from the conventional injection and the PEGylated liposomes best fit the Weibull equation (Table 5). The overall $R^2$ values for both the elemene injection and the PEGylated liposomes can be attributed to the Weibull model release pattern. These results indicate that the PEGylated liposomal formulations meet the requirement for a sustained drug delivery system compared to the conventional injection.

**Stability studies**

Stability is one of the major obstacles for the formulation of liposomes because of the aggregation and leaching of drugs from the lipid layers. Moreover, liposomes are easy to oxidize because they are made up of lipids; hence, stability is the major problem for liposome storage46,47. The physical stability results of PEG-Lipo-β-E for different times are shown in Table 6.

**Table 3**  Stability (%) of β-E in rat plasma ($n = 5$)

| Nominal concentration (μg/mL) | Room temperature$^a$ | Autosampler$^b$ | Freeze-thaw$^c$ | −20 °C for 48 hours |
|-------------------------------|---------------------|----------------|----------------|-------------------|
| LQC (0.6)                    | 93.7 ± 1.0          | 94.8 ± 2.8     | 96.38 ± 1.0    | 98.0 ± 3.0        |
| MQC (2)                      | 97.1 ± 0.9          | 99.6 ± 2.3     | 95.9 ± 0.7     | 101.0 ± 3.4       |
| HQC (10)                     | 95.4 ± 0.5          | 103.1 ± 2.2    | 98.99 ± 4.6    | 103.37 ± 0.3      |

LQC, low quality control; MQC, middle quality control; HQC, high quality control; $^a$room temperature during 4 hours; $^b$25 °C during 24 hours in the autosampler; $^c$3 freezing and thawing cycles.

**Table 4**  Durability (%) of β-E in rat plasma ($n = 3$)

| Analytes | Method parameter                        | Durability (%) |
|----------|-----------------------------------------|----------------|
| MQC (2)  | Flow rate: 0.98 mL/minute               | 98.5 ± 2.2     |
|          | Flow rate: 1.02 mL/minute               | 93.0 ± 0.5     |
|          | Acetonitrile/water (78:22)              | 94.0 ± 3.4     |
|          | Acetonitrile/water (82:18)              | 101.4 ± 1.9    |
|          | Temperature 38 °C                       | 95.6 ± 1.0     |
|          | Temperature 42 °C                       | 94.7 ± 0.3     |

MQC, middle quality control.

**Figure 5**  In vitro release and the plasma concentration-time curves of elemene injection and PEG-Lipo-β-E. (A) In vitro release of β-E from elemene injection and PEG-Lipo-β-E containing 5.024 mg/mL β-E ($n = 3$). (B) The mean plasma concentration of β-E-vs.-time curves after intravenous injection of PEG-Lipo-β-E and elemene injection ($n = 5$). Con., concentration.
After a storage period of 30 days, the liposomes showed no significant change in β-E content and physical appearance (no precipitation, no flocculation and delamination, uniform dispersion, good fluidity, and obvious opalescence to light), with a slight change in EE, which decreased by 4% of the original value. The particle size of PEG-Lipo-β-E under storage conditions increased by 2% of the original value. The particle size of PEG-Lipo-β-E under storage conditions increased by 2% of the original value. In general, PEG-Lipo-β-E are stable at 4 °C for 30 days. The reason is that the DSPE-PEG 2000 chain on the surface of the liposomes can prevent the accumulation of liposomes, providing stability of the formulation.

**Pharmacokinetics of PEG-Lipo-β-E**

Pharmacokinetic studies were performed to compare PEG-Lipo-β-E to an elemene injection by determining the drug concentration in rat plasma up to 90 minutes after i.v. administration. The plasma concentration vs. time curves for the PEG-Lipo-β-E and elemene injection are shown in Figure 5B. The mean plasma concentrations decreased in both groups. At the first 5 time points, plasma β-E concentrations were higher in the PEG-Lipo-β-E group than in the elemene injection group. The main pharmacokinetic parameters examined in this study are shown in Table 7. Parameters, such as the mean residence time (MRT) and steady-state apparent volume of distribution ($V_s$), showed no significant differences between the 2 groups ($P > 0.05$). However, compared to the elemene injection group, the PEG-Lipo-β-E group demonstrated a 1.75-fold decrease in clearance ($CL_{f}$) and a 1.62-fold increase in half-life ($T_{1/2}$). In addition, the area under the concentration-time curve (AUC) after injection of PEG-Lipo-β-E was 1.76 times higher than after elemene injection administration ($P < 0.05$). The higher AUC, longer half-life and slower clearance of PEG-Lipo-β-E compared to the elemene injection demonstrated that the availability of β-E is increased by forming PEGylated liposomes.

### Table 5 Nonlinear fits of β-E release from elemene injection and PEGylated liposomes

| Equation type          | Elemene injection | PEG-Lipo-β-E |
|------------------------|-------------------|--------------|
|                        | Equation         | $R^2$        | Equation         | $R^2$        |
| Zero-order model, $F = K_0 \times t$ | $F = 3.150 \times t$ | 0.3520 | $F = 2.289 \times t$ | 0.6869 |
| First-order model, $F = 100 \times (1 - e^{-0.101t})$ | $F = 100 \times (1 - e^{-0.042t})$ | 0.9375 | $F = 100 \times (1 - e^{-0.042t})$ | 0.9301 |
| Higuchi model, $F = K_n \times t^{0.5}$ | $F = 16.839 \times t^{0.5}$ | 0.8838 | $F = 11.913 \times t^{0.5}$ | 0.9836 |
| Weibull model, $F = 100 \times [1 - e^{-\beta t^{\alpha}}]$ | $F = 100 \times [1 - e^{-\beta t^{\alpha}}]$ | 0.9511 | $F = 100 \times [1 - e^{-\beta t^{\alpha}}]$ | 0.9909 |

$F$, the fraction (%) of drug released in time $t$; $K_0$, $K_1$, and $K_n$, the zero-order, first-order, and Higuchi release constant, respectively; $\alpha$, the scale parameter which defines the time scale of the process; $\beta$, the shape parameter which characterizes the curve as either exponential ($\beta = 1$; case 1), sigmoid, S-shaped, with upward curvature followed by a turning point ($\beta > 1$; case 2), or parabolic, with a higher initial slope and after that consistent with the exponential ($\beta < 1$; case 3).

### Table 6 Entrapment efficiency, mean particle size, appearance and β-E content of PEG-Lipo-β-E formulations at 4 °C ($n = 3$)

| Time (days) | Appearance | Entrapment efficiency (%) | Particle size (nm) | β-E content (mg/mL) |
|-------------|------------|----------------------------|--------------------|---------------------|
| 0           | Uniform    | 95.53 ± 1.712              | 83.31 ± 0.181      | 5.024 ± 0.107       |
| 7           | Uniform    | 92.61 ± 0.782              | 83.25 ± 0.217      | 5.018 ± 0.091       |
| 15          | Uniform    | 92.93 ± 1.542              | 83.83 ± 1.418      | 4.985 ± 0.043       |
| 30          | Uniform    | 91.44 ± 3.926              | 85.09 ± 1.701      | 4.983 ± 0.018       |

### Table 7 Pharmacokinetic parameters in rats after intravenous administration of PEG-Lipo-β-E and elemene injection

| Parameters     | Units      | Elemene injection | PEG-Lipo-β-E |
|----------------|------------|-------------------|--------------|
| AUC$_{(0-t)}$  | mg/L*min   | 69.951 ± 14.118   | 123.331 ± 3.265* |
| MRT$_{(0-t)}$  | min        | 17.175 ± 1.591    | 15.989 ± 0.599 |
| T$_{1/2}$      | min        | 15.964 ± 1.938*   | 25.850 ± 0.609* |
| $V_s$          | L/kg       | 0.428 ± 0.219     | 0.258 ± 0.046  |
| $CL_{f}$       | L/min/kg   | 0.014 ± 0.003*    | 0.008 ± 0.000* |

The data are represented as the mean ± SD ($n = 5$). AUC, area under the concentration-time curve; MRT, mean residence time; $T_{1/2}$, half-life; $V_s$, steady-state apparent volume of distribution; $CL_{f}$, clearance. *$P < 0.05$ was considered statistically significant.
In vitro cytotoxicity studies in human bladder cancer cells

A CCK-8 assay was used to evaluate the effect of free β-E, elemene injection and PEG-Lipo-β-E on cell proliferation in T24 cells and KU-19-19 cells (Figure 6). A concentration-dependent decline in the percent of cell survival was observed upon treatment with 2 preparations at all the studied time points. After 24 hours of incubation, we found that free β-E could promote cell growth at concentrations of 25, 50, 75 and 100 µg/mL in T24 cells and KU-19-19 cells. The inhibition rate of 100 µg/mL free β-E in T24 cells was 25.5%, while the IC_{50} of free β-E in KU-19-19 cells was 97.27 µg/mL after 48 hours of incubation. The IC_{50} value of the elemene injection in T24 cells was 91.41 and 92.90 µg/mL at 24 hours and 48 hours, respectively, while the IC_{50} of PEG-Lipo-β-E in T24 cells was 102.33 and 72.78 µg/mL at 24 hours and 48 hours, respectively. Similarly, in KU-19-19 cells, the IC_{50} value of the elemene injection was 63.24 and 71.45 µg/mL at 24 and 48 hours, respectively, whereas the IC_{50} value of PEG-Lipo-β-E was 48.19 and 47.53 µg/mL at 24 and 48 hours of incubation, respectively.

Compared to 24 hours of incubation, the IC_{50} value of the elemene injection showed a slight increase in T24 cells and a 1.13-fold increase in KU-19-19 cells at 48 hours, while the PEG-Lipo-β-E demonstrated a 1.41-fold decrease in IC_{50} in T24 cells and a slight decrease in KU-19-19 cells at 48 hours of incubation. PEG-Lipo-β-E showed more cytotoxicity at 48 hours, and the number of viable T24 cells and KU-19-19 cells was found to be less after incubation with PEG-Lipo-β-E. Compared to elemene injection, although the PEG-Lipo-β-E demonstrated a 1.12-fold increase in the IC_{50} in T24 cells at 24 hours, the IC_{50} value was 1.28-fold less at 48 hours; in KU-19-19 cells, the PEG-Lipo-β-E showed a 1.31- and 1.50-fold decrease in IC_{50} at 24 hours and 48 hours, respectively. β-E in the free and encapsulated forms exhibited better cytotoxicity against KU-19-19 cell lines compared to T24 cell lines. These data suggest a prolonged anticancer effect of PEGylated liposomes when compared with free β-E and conventional injection.

In vitro cell migration assay

As cell migration was closely related to tumor metastasis, cell motility was examined by wound healing and Transwell migration assays. An aggressive bladder cancer cell line, KU-19-19, was selected for this experiment (Figure 7).
The CCK-8 assay showed that 30 µg/mL β-E did not exert obvious cytotoxicity under the tested cell conditions. In the control group, the forming scratch gap was barely observed after 36 hours, indicating that the KU-19-19 cells had strong motility. PEG-Lipo did not affect cell migration. Free β-E and PEG-Lipo-β-E could prevent cell motility, and the wound closure of the PEG-Lipo-β-E group could be greatly reduced after 36 hours. In the Transwell migration assay, there was almost no inhibitory effect from PEG-Lipo, and the inhibitory effect of free β-E was slight. However, a significant inhibitory effect was observed in the PEG-Lipo-β-E group. These results suggest that PEG-Lipo-β-E not only enhances cell cytotoxicity but also inhibits cell migration.

In vivo antitumor efficacy

The antitumor effect of PEG-Lipo-β-E was evaluated in KU-19-19 bladder tumor-bearing BALB/c nude female mice by assessing the TV variation over time. As shown in Figure 8A and 8C and Table 8, the TV in the blank liposome treatment group increased rapidly over time. In contrast, the RTV was significantly lower in mice treated with elemene injection and PEG-Lipo-β-E at doses of 50 mg/kg. In addition, TGI was higher with PEG-Lipo-β-E treatment (45.67%) compared to elemene injection (33.10%) (P < 0.05). These results suggest that the antitumor efficacy of PEG-Lipo-β-E is enhanced, an effect that may be attributed to increased bioavailability.

Safety evaluation

The body weight variation was evaluated during treatment as an indicator of toxicity. As seen in Figure 8B, although a slight body weight loss was observed in the elemene injection and PEG-Lipo-β-E group compared with the blank liposome treatment group, there were no significant differences (P > 0.05), indicating the good safety profiles of the nanoparticles. The elemene injection group also showed a slight weight loss than the PEG-Lipo-β-E group, indicating that the PEG-Lipo-β-E might have better safety than the elemene injection. In addition, histological analysis of different organs was performed at the end of the treatment period (Figure 8D), no significant pathological features such as endothelial cell damage, necrosis, inflammatory response, and regenerative changes were observed in the experimental group compared with the control group. This evaluation revealed no evidence of toxicity to the heart, kidney, liver, lung, or spleen of the animals.

Discussion

The results of the present study demonstrate that PEGylated β-E liposomes were successfully developed with a pH of 6.65 and demonstrated good stability after being stored for 30 days. As biodegradable and essentially nontoxic vesicles, stealth liposomes have been used as delivery systems for
Figure 8  In vivo antitumor effect and safety evaluation of PEG-Lipo-β-E and elemene injection. (A) Variation of TV after treatment with PEG-Lipo, elemene injection and PEG-Lipo-β-E at a dose of 50 mg/kg after 16 days. (B) Body weight changes during treatment with different formulations. (C) Photographs of KU-19-19 bladder tumor-bearing BALB/c nude female mice and tumors. (D) Histological analysis (20 ×) of different organs after treatment with different formulations.

Table 8  RTV and TGI after administration of PEG-Lipo, elemene injection and PEG-Lipo-β-E

| Treatment                | RTV      | TGI (%) |
|--------------------------|----------|---------|
| PEG-Lipo                 | 22.06 ± 5.02 | –       |
| Elemene injection 50 mg/kg | 16.65 ± 3.09* | 33.10  |
| PEG-Lipo-β-E 50 mg/kg    | 12.82 ± 1.36* | 45.67  |

The data are represented as the mean ± SD (n = 5). RTV, relative tumor volume; TGI, tumor growth inhibition. *P < 0.05 was considered statistically significant.

many antitumor drugs^{31,48-50}. In the present study, PEGylated liposomes were prepared by ethanol injection and high-pressure micro-jet homogenization. This method is simple and rapid, and the possibility of denaturation of sensitive components is small. This method is mild to lipids and encapsulated materials, and the volume of ethanol in the medium is only 2%, which can reduce residual organic solvents. To improve the stability of liposomes, the oxidative degradation of the liposome component phospholipids should be prevented during preparation. The hydrolysis of soybean phospholipids is mainly catalyzed by hydrogen ions and hydroxide ions, and the hydrolysis rate is the smallest at a pH of approximately 6.5^{51}. In this study, L-histidine was used instead of disodium hydrogen phosphate and sodium dihydrogen phosphate in the conventional elemene injection to adjust the pH of the solution, on the one hand, to reduce the
hydrolysis of soybean phospholipids, and on the other hand, to reduce irritation of the liposomes.

FTIR and DSC are commonly available tools to provide information about the physicochemical state of liposomes. In order to prevent the influence of water, the PEG-Lipo-β-E was freeze-dried before measurement. During the thermal analysis, we also investigated the heat flow changes of β-E at 0 to 80 °C. β-E has no endothermic peaks and an exothermic peak because β-E is an oily liquid at normal temperature. Therefore, we verified the formation of liposomes by comparing liposome materials, as well as the formation of blank and drug-containing liposomes. The results showed that the phase transition temperature was increased after the formation of liposomes for β-E, and the heat flow changed significantly.

Both gas chromatography and liquid chromatography can be used for the determination of β-E. We found that the quantitative results obtained by gas chromatography were inaccurate and the repeatability was poor, probably because β-E was easily volatilized. UFLC could improve the separation effect, speed up the detection, and facilitate batch and rapid analysis. The detection time of liquid chromatography is 4 times shorter than that of gas chromatography. In the test, methanol:water (80:20) was used as the mobile phase, but the baseline was unstable and there was a tailing phenomenon. The mobile phase was adjusted to be acetonitrile-water, which could obviously improve the peak shape and separation. In the process of plasma samples treatment, by comparing the methanol and acetonitrile, we found that acetonitrile could precipitate proteins better. In the determination of the plasma sample content, we found that the concentration of the drug in the sample was not high after adding 1.3 mL of acetonitrile to 0.2 mL of plasma. Therefore, we adjusted the ratio of plasma to acetonitrile (1:4) to obtain a larger amount of β-E for detection. During the processing of plasma samples, it is often necessary to add internal standards to eliminate errors in sample pretreatment and determination. The UFLC method used in this study had been reported in a related study. The recovery and matrix effects of the sample after simple protein precipitation by acetonitrile meet the requirements. Therefore, we did not quantify using the internal standard method, which is not rigorous in this study. This method needs to be improved in subsequent studies to ensure the accuracy of the measurement.

β-E is a water-insoluble volatile oil with a lighter density than water. The free β-E in the liposomes should float on the surface of the water. We had not been able to separate and determine free β-E by Sephadex column chromatography as the insoluble β-E floating on water might be adsorbed by the gel particles, resulting in recovery that did not meet the requirements. Therefore, the EE of PEG-Lipo-β-E was obtained by determining the drug concentration of the internal and total solutions using the liquid surface method.

The higher AUC, longer half-life and slower clearance of PEG-Lipo-β-E compared to the elemene injection demonstrated that the availability of β-E is increased by forming PEGylated liposomes. The PEGylated liposome exhibited a slow release as the loaded drug required a transfer from the PEG to the aqueous phase. The mechanism might be that DSPE-PEG 2000 produced a nano-thickness steric layer on the surface of the liposome. This steric hindered layer acts similar to a “brush” that excludes other macromolecules or lipoprotein complexes away from the liposome, thereby weakening the effects of various components of the blood, especially the effect of blood plasma opsonins, and subsequent RES uptake. Furthermore, DSPE-PEG 2000 has a long polar group that increases the hydrophilicity of the liposome surface, thereby reducing the rate and extent of liposome uptake by the mononuclear phagocytic system (MPS). At the same time, this long polar group effectively prevents the surface of the liposomes from interacting with plasma albumin and reduces the affinity of the liposomes to MPS. Thus, PEG-Lipo-β-E produced higher plasma concentrations.

From the results of in vitro cytotoxicity studies in human bladder cancer cells, it is evident that the cytotoxic effects of free β-E at 24 or 48 hours of treatment are not good, especially at 24 hours of incubation, which may be due to the volatility and poor bioavailability of the pure drug. The promotion of cell growth might be because the surviving fraction of cells in the population are able to proliferate in the cell culture at longer incubation times and in turn increase the percent of viable cells. However, for the 2 preparations, the 24- and 48-hour assays showed a significant reduction in the cell survival rate when compared with the pure drug. Moreover, it is striking to note that the cytotoxic effects of PEG-Lipo-β-E significantly increased, and the percent of viable cells remained lower compared to the elemene injection. This remarkable enhancement in cytotoxicity is due to the slow release of the drug from DSPE-PEG 2000. The anticancer effects of PEG-Lipo-β-E remained constant or increased for the longer incubation time (48 hours), but in the case of the conventional injection, a decline in the activity was observed after 48 hours of incubation.
The evaluation of the antitumor effect of treatment with PEG-Lipo-β-E in a bladder cancer xenograft model showed that the TGI of PEG-Lipo-β-E is enhanced. Elemene injection and PEG-Lipo-β-E could target of tumors via the enhanced permeability and retention effect. After the common elemene injection entered the body, it was quickly removed from the body, making it difficult to exert a better anti-tumor effect. Because of the existence of the stealth component (DSPE-PEG 2000), long-circulating liposomes had prolonged retention time in the body, which meant β-E had more opportunities to passively target tumors, and the curative effect was improved. The safety of PEG-Lipo-β-E was also evaluated by body weight variation and histological analysis of different organs. Compared with chemotherapy drugs, β-E is a nontoxic antitumor drug extracted from the herb Curcumaee Rhizoma. There was no evidence of toxicity to the heart, kidney, liver, lung, or spleen of the animals in PEG-Lipo-β-E group by histological analysis. Moreover, there was no obvious weight loss in the PEG-Lipo-β-E group than the PEG-Lip group, indicating that the safety was good. Therefore, the results from this study suggest the potential applicability of PEG-Lipo-β-E as a new and promising anticancer formulation.

Conclusions

The present study demonstrates the PEG-Lipo-β-E as a new formulation with ease of preparation, high EE, good stability, improved bioavailability and anti-tumor effects. Therefore, the PEGylated β-elemene liposome may have potential uses as an anticancer drug formulation in the future.

Acknowledgments

This work was supported by grants from National Natural Science Foundation of China (Grant No. 81672932, 81874380 and 81730108), Zhejiang Provincial Natural Science Foundation of China for Distinguished Young Scholars (Grant No. LR18H160001), Zhejiang Provincial Natural Science Foundation of China (Grant No. LY15H160028 and LY13H130002), the Science and Technology Development Fund, Macau SAR (130/2017/A3, 0099/2018/A3), Zhejiang Province Medical Science and Technology Project (Grant No. 2017RC007), Key Project of Zhejiang Province Ministry of Science and Technology (Grant No. 2015C03055), Talent Project of Zhejiang Association for Science and Technology (Grant No. 2017YCGC002), Zhejiang Province Science and Technology Project of TCM (Grant No. 2019ZZ016), Key Project of Hangzhou Ministry of Science and Technology (Grant No. 20162013A07, 20142013A63) and Zhejiang Provincial Project for the Key Discipline of Traditional Chinese Medicine (Grant No. 2017-XK-A09).

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. Jiang ZY, Jacob IA, Loganathachetti DS, Nainangu P, Chen BA. β-Elemene: mechanistic studies on cancer cell interaction and its chemosensitization effect. Front Pharmacol. 2017; 8: 105.
2. Zhang GN, Ashby Jr CR, Zhang YK, Chen ZS, Guo HQ. The reversal of antineoplastic drug resistance in cancer cells by β-elemene. Chin J Cancer. 2015; 34: 45.
3. Cai XY, Zhang M, Yang XH, Gu JQ. Effect of the inhibiting function of β-elemene on paclitaxel-resistant human lung cell and Wnt/β-catenin signaling pathway. Acta Univ Tradit Med Sinensis Pharmacol Shanghai. 2016; 30: 55-9.
4. Liang D, Yang MW, Guo BL, Cao JI, Yang L, Guo XD. β-Elemene promotes the apoptosis to cells of MG-63 by blocking the WNT signaling pathway. Chin Pharmacol Bull. 2011; 27: 1776.
5. Wang LF, Zhao YY, Wu Q, Guan YF, Wu X. Therapeutic effects of β-elemene via attenuation of the Wnt/β-catenin signaling pathway in cervical cancer cells. Mol Med Rep. 2018; 17: 4299-306.
6. Zhu TZ, Li XM, Luo LH, Wang XG, Li ZQ, Xie P, et al. Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules. J Transl Med. 2015; 13: 356.
7. Feng HB, Wang J, Jiang HR, Mei X, Zhao YY, Chen FR, et al. β-Elemene selectively inhibits the proliferation of glioma stem-like cells through the downregulation of notch1. Stem Cells Transl Med. 2017; 6: 830-9.
8. Meng X, Song Y, Liu YP, Yang XH. Activation of notch signal pathway in the process of differentiation of endothelial progenitor cells derived from rat bone marrow and intervention mechanism of β-elemene in it. Chin J Cancer Prev Treat. 2012; 19: 489-93.
9. Yan B, Zhou YQ, Feng SH, Lv C, Xiu LJ, Zhang YC, et al. β-Elemene-attenuated tumor angiogenesis by targeting notch-1 in gastric cancer stem-like cells. Evid Based Complement Alternat Med. 2013; 2013: 268468.
10. Li L, Xu L, Qu XJ, Zhao MF, Yu P, Kang J, et al. Cbl-regulated akt and erk signals are involved in β-elemene-induced cell apoptosis in lung cancer cells. Mol Med Rep. 2011; 4: 1243-6.
11. Tong EJ, Xu YH, Li GQ, Zou K, Zou LJ. The effects of β-elemene on the expression of mtor, hif-1α, survivin in lung adenocarcinoma A549 cell. Afr J Tradit Complement Altern Med. 2013; 10: 18-23.
12. Zhan YH, Liu J, Xu X, Hou KZ, Wang KF, Liu YP, et al. B-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/mTOR signalling pathways. Asian Pac J Cancer Prev. 2012; 13: 2739-44.

13. Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ, Xu YH. Anti-tumor effect of β-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett. 2008; 264: 127-34.

14. Zhao SY, Wu JJ, Zheng F, Tang Q, Yang LJ, Li LN, et al. β-Elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPK signaling pathways in human lung cancer cells: the role of sp1. J Cell Mol Med. 2015; 19: 630-41.

15. Zhu TZ, Li XM, Luo LH, Xu YH, Cao P, Liu Y, et al. β-Elemene inhibits proliferation through crosstalk between glia maturation factor β and extracellular signal-regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells. Mol Med Rep. 2014; 10: 1122-8.

16. Li RR, Shi HJ, Ren QY, Zheng J, Ding JY, Wang K. The mechanism of β-elemene suppressing HepG2 cell invasion and migration. Mod Oncol. 2016; 24: 1870-5.

17. Zheng F, Tang Q, Zheng XH, Wu JJ, Huang HD, Zhang HB, et al. Inactivation of Stat3 and crosstalk of miRNA155-5p and FOXO3a contribute to the induction of IGFBP1 expression by beta-elemene in human lung cancer. Exp Mol Med. 2018; 50: 121.

18. Huang CY, Yu YF. Synergistic cytotoxicity of β-elemene and cisplatin in gingival squamous cell carcinoma by inhibition of STAT3 signaling pathway. Med Sci Monit. 2017; 23: 1507-13.

19. Wu JJ, Tang Q, Yang LJ, Chen YQ, Zheng F, Han SS. Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells. Sci Rep. 2017; 7: 509.

20. Wu DW, Lv DW, Zhang T, Guo LY, Ma FL, Zhang CH, et al. Antitumor effects of β-elemene via targeting the phosphorylation of insulin receptor. Endocr-Relat Cancer. 2019; 26: 187-99.

21. Cheng H, Ge X, Zhuo S, Gao Y, Zha B, Zhang J, et al. β-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating ezH2. Front Pharmacol. 2018; 9: 1413.

22. Cai B, Ma LM, Nong SJ, Wu Y, Guo X, Pu JX. β-Elemene induced anticancer effect in bladder cancer through upregulation of PTEN and suppression of AKT phosphorylation. Oncol Lett. 2018; 16: 6019-25.

23. Lin L, Li LB, Chen XQ, Zeng BW, Lin TY. Preliminary evaluation of the potential role of β-elemene in reversing erlotinib-resistant human NSCLC A549/ER cells. Oncol Lett. 2018; 16: 3380-88.

24. Chen MW, Wang SP, Tan M, Wang YT. Applications of nanoparticles in herbal medicine: Zedoary turmeric oil and its active compound β-elemene. Am J Chin Med. 2011; 39: 1093-102.

25. Zhai BT, Zeng YY, Zeng ZW, Zhang NN, Li CX, Zeng YJ, et al. Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy. Int J Nanomed. 2018; 13: 6279-96.

26. Kheiri Manjili H, Ghasemi P, Malvandi H, Mousavi MS, Attari E, Danafar H. Pharmacokinetics and in vivo delivery of curcumin by copolymeric MPEG-PCL micelles. Eur J Pharm Biopharm. 2017; 116: 17-30.

27. Shakeri-Zadeh A, Shiran MB, Khoei S, Sharifi AM, Ghaznavi H, Khoei S. A new magnetic nanoparticle containing 5-fluorouracil: in vivo drug release, anti-tumor, and pro-apoptotic effects on CT26 cells allograft model. J Biomater Appl. 2014; 29: 548-56.

28. Shakeri-Zadeh A, Khoei S, Shiran MB, Sharifi AM, Khoei S. Synergistic effects of magnetic drug targeting using a newly developed nanoparticle and tumor irradiation by ultrasound on CT26 tumors in BALB/c mice. J Mater Chem B. 2015; 3: 1879-87.

29. Abed Z, Khoei S, Ghalandari B, Beik J, Shakeri-Zadeh A, Ghaznavi H, et al. The measurement and mathematical analysis of 5-Fu release from magnetic polymeric nanoparticles, following the application of ultrasound. Anti-Cancer Agents Med Chem. 2018; 18: 438-49.

30. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006; 1: 297-315.

31. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in kaposi’s sarcoma. Semin Oncol. 2004; 31: 36-52.

32. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori. 2003; 89: 257-49.

33. Oude Blenke E, Mastrobattista E, Schifflers RM. Strategies for triggered drug release from tumor targeted liposomes. Expert Opin Drug Deliv. 2013; 10: 1399-410.

34. Shavi GV, Seenivasra Reddy M, Raghavendra R, Nayak UY, Kumar AR, Deshpande PB, et al. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation. J Liposome Res. 2016; 26: 28-46.

35. Dhoble S, Patravale V. Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach. Drug Deliv Transl Res. 2019; 9: 980-96.

36. Handali S, Moghimipour E, Rezaei M, Ramezani Z, Kouchak J, et al. PEGylated β-elemene-inhibited growth of nasopharyngeal carcinoma cells. Eur J Pharm Biopharm. 2017; 116: 17-30.
glucoevatromonoside derivative induce potent antitumor response. Biomed Pharmacother. 2018; 108: 1152-61.
42. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javannard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018; 10: 57.
43. Chaves MA, Pinho SC. Curcumin-loaded proliposomes produced by the coating of micronized sucrose: influence of the type of phospholipid on the physicochemical characteristics of powders and on the liposomes obtained by hydration. Food Chem. 2019; 291: 7-15.
44. Handali S, Moghimipour E, Kouchak M, Ramezani Z, Amini M, Angali KA, et al. New folate receptor targeted nano liposomes for delivery of 5-fluorouracil to cancer cells: strong implication for enhanced potency and safety. Life Sci. 2019; 227: 39-50.
45. Zhang Y, Huo MR, Zhou JP, Zou AF, Li WZ, Yao CL, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010; 12: 263-71.
46. Franzé S, Samaritani E, Minghetti P, Cilurzo F. Lyophilization of liposomal formulations: still necessary, still challenging. Pharmaceutics. 2018; 10: 139.
47. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4: 145-60.
48. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. 2005; 25: 3031-9.
49. Vokes EE, Gordon GS, Mauer AM, Rudin CM, Krauss SA, Szeto L, et al. A phase I study of STEALTH® cisplatin (SPI-77) and vinorelbine in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2000; 2: 128-32.
50. Zamboni WC, Gervais AC, Egorin MJ, Schellens JHM, Zuhowski EG, Pluim D, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2004; 53: 329-36.
51. Grit M, Underberg WJM, Crommelin DJA. Hydrolysis of saturated soybean phosphatidylcholine in aqueous liposome dispersions. J Pharm Sci. 1993; 82: 362-6.
52. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999; 51: 691-743.
53. Zhang XY, Zhang SH, Kang Y, Huang KQ, Gu ZP, Wu J. Advances in long-circulating drug delivery strategy. Curr Drug Metab. 2018; 19: 750-8.

Cite this article as: Zhai B, Wu Q, Wang W, Zhang M, Han X, Li Q, et al. Preparation, Characterization, Pharmacokinetics and Anticancer Effects of PEGylated β-Elemene Liposomes. Cancer Biol Med. 2020; 17: 60-75. doi: 10.20892/j.issn.2095-3941.2019.0156